A somatostatin blood test measures a hormone that acts as a broad inhibitor of endocrine and digestive activity. Somatostatin is produced by delta cells in the pancreas, specialized cells in the stomach and intestine, and neurons in the hypothalamus and other parts of the nervous system. It suppresses insulin, glucagon, growth hormone, gastrin, pancreatic enzymes, gallbladder contraction, and intestinal secretion. The blood test is highly specialized and is used mainly when symptoms and imaging raise concern for a somatostatin-secreting neuroendocrine tumor. High levels may accompany a rare pancreatic or duodenal somatostatinoma, but mild elevations can be nonspecific and results are vulnerable to collection and assay problems. A normal value does not rule out a neuroendocrine tumor, especially if the tumor is nonfunctional or secretion is intermittent. The sample often requires a prechilled EDTA tube, immediate plasma separation, and freezing. Interpretation depends on the laboratory method, fasting status, symptoms, medicines such as somatostatin analogs, and companion tests for glucose, gallbladder disease, malabsorption, anemia, and tumor localization.
- Somatostatin testing is not a routine wellness, diabetes, or pancreatic-function test.
- The classic somatostatinoma syndrome combines diabetes or hyperglycemia, gallstones, steatorrhea or diarrhea, and weight loss, but many tumors are clinically silent.
- A high value must be confirmed in the context of proper fasting collection and rapid frozen processing.
- Somatostatin analog medicines can complicate interpretation and should never be stopped without specialist instructions.
- Diagnosis of a neuroendocrine tumor requires clinical, biochemical, imaging, and often tissue evidence—not one hormone result.
Table of Contents
- What Somatostatin Does
- Why the Blood Test Is Ordered
- Preparation and Specimen Handling
- Normal Range and Result Interpretation
- Causes of High Somatostatin
- Somatostatinoma Symptoms and Diagnosis
- Low Levels and Related Tests
- Limitations, Follow-Up, and Treatment
What Somatostatin Does
Somatostatin is also called somatotropin release-inhibiting factor because it was first recognized for suppressing growth hormone. Two biologically active forms, containing 14 or 28 amino acids, are produced from a larger precursor. They act through five somatostatin receptor subtypes distributed across endocrine, nervous, gastrointestinal, and immune tissues.
In the pancreas, delta cells release somatostatin locally within the islets. The hormone reduces both insulin secretion from beta cells and glucagon secretion from alpha cells. This paracrine action helps fine-tune glucose regulation rather than simply pushing glucose in one direction.
In the gastrointestinal tract, somatostatin inhibits:
- Gastrin and gastric acid secretion
- Secretin, cholecystokinin, and several gut peptides
- Pancreatic enzyme and bicarbonate release
- Gallbladder contraction and bile flow
- Intestinal water and electrolyte secretion
- Splanchnic blood flow and gastrointestinal motility
In the hypothalamus and pituitary system, it suppresses growth hormone and thyroid-stimulating hormone. It also acts as a neurotransmitter and has antiproliferative effects in some cells.
These broad inhibitory actions explain the symptoms of hormone excess. Too much circulating somatostatin can reduce insulin enough to produce hyperglycemia or diabetes, inhibit cholecystokinin and gallbladder emptying enough to promote gallstones, and suppress pancreatic enzymes and intestinal absorption enough to cause diarrhea, steatorrhea, nutrient deficiency, and weight loss.
Normal somatostatin is mostly active close to where it is released and has a short half-life. Circulating concentrations are low, and specialized extraction immunoassays are often required. A blood value is therefore less robust than common tests such as glucose or thyroid-stimulating hormone.
Somatostatin should not be confused with somatotropin, which is growth hormone, or with somatomedin C, which is insulin-like growth factor 1. It should also be distinguished from synthetic somatostatin analogs such as octreotide, lanreotide, and pasireotide. These medicines activate selected receptor subtypes and are used to control hormone secretion or tumor growth in several endocrine disorders.
Why the Blood Test Is Ordered
The primary reason to order a plasma somatostatin level is suspicion of somatostatinoma, an exceptionally rare functional neuroendocrine tumor. The test is most appropriate when the clinical pattern, imaging, or pathology suggests excess secretion.
Potential clues include:
- New diabetes or unexplained worsening hyperglycemia
- Gallstones or gallbladder dysfunction
- Chronic diarrhea or fatty, difficult-to-flush stools
- Unintentional weight loss
- Abdominal pain
- Anemia or nutrient deficiencies
- A pancreatic, duodenal, or periampullary mass
- A neuroendocrine tumor with unclear hormone syndrome
Somatostatinomas may arise in the pancreas or duodenum and less commonly elsewhere in the gastrointestinal tract. Pancreatic tumors are more likely to produce the full hormonal syndrome, while duodenal tumors are often smaller, associated with the ampullary region, and may be discovered because of pain, jaundice, bleeding, or obstruction rather than hormone excess.
The test may also be used to monitor a known secreting tumor if the level was clearly elevated before treatment and consistently tracks disease. Serial testing should ideally use the same laboratory and method under comparable collection conditions.
Somatostatin testing is not recommended as an untargeted screen for:
- Common type 2 diabetes
- Hypoglycemia
- Acromegaly
- Irritable bowel syndrome
- Ordinary gallstones
- Chronic pancreatitis
- Pancreatic adenocarcinoma
- General fatigue or weight change
Those conditions are common, while somatostatinoma is extraordinarily rare. Random testing in low-risk people is more likely to produce a false-positive or uninterpretable result than a useful diagnosis.
A clinician evaluating chronic diarrhea usually begins with stool characteristics, duration, medication and laxative review, infection risk, celiac disease, inflammatory disease, malabsorption, thyroid function, and routine chemistry. A hormone panel is selected only when the pattern is secretory, severe, fasting-persistent, or accompanied by a tumor syndrome.
Similarly, a pancreatic mass should be assessed with imaging characteristics, ductal anatomy, relevant tumor markers, and tissue when indicated. A somatostatin level is an adjunct, not a substitute for radiology or histology.
Preparation and Specimen Handling
Somatostatin is a fragile peptide, so collection quality is essential. One current clinical method requires plasma collected into a prechilled EDTA tube, separation from blood cells as soon as possible, transfer to a transport vial, and immediate freezing. Room-temperature or refrigerated transport may be rejected.
Fasting is commonly recommended, even when not stated in every directory, because meals stimulate gastrointestinal peptide release and can add variability. The ordering laboratory’s instructions should be followed exactly. Water is usually permitted during the fast.
Before collection, the clinician should document:
- Current somatostatin analog therapy
- Proton pump inhibitors and other gastrointestinal medicines
- Diabetes medicines and glucose status
- Recent endoscopy, surgery, or acute illness
- Kidney and liver function
- Fasting duration and time of day
- Known neuroendocrine tumor diagnosis and treatment
Octreotide, lanreotide, and pasireotide can alter endogenous hormone secretion and may interfere directly or indirectly with interpretation. Long-acting preparations remain active for weeks. A patient should never delay or stop a dose solely to obtain a test unless the specialist coordinates the timing.
The sample should be collected by staff familiar with the send-out requirements. The tube may need to be placed on ice, centrifuged promptly, aliquoted, and frozen within a narrow window. Repeated freeze-thaw cycles should be avoided. Gross hemolysis, lipemia, or icterus can lead to rejection in some methods.
Because turnaround may be one to several weeks, somatostatin testing is not useful for acute stabilization. Severe dehydration, uncontrolled hyperglycemia, gastrointestinal bleeding, obstruction, or acute abdominal pain must be managed immediately based on standard clinical findings.
A surprising result should prompt a discussion with the laboratory. Questions include whether the assay measures total immunoreactive somatostatin, which molecular forms it recognizes, whether therapeutic analogs cross-react, and whether specimen conditions were acceptable.
If serial monitoring is planned, use the same method. Different immunoassays may not produce interchangeable numbers, even when both report picograms per milliliter.
Normal Range and Result Interpretation
Somatostatin is usually reported in picograms per milliliter. One current extraction immunoassay lists an adult reference limit of 30 pg/mL or less. Another clinical laboratory lists less than 25 pg/mL. These differences illustrate why the range printed on the actual report must be used.
The result can be interpreted in broad categories:
| Result context | General interpretation |
|---|---|
| Within the laboratory range and no compatible syndrome | Somatostatin excess is unlikely, but a nonfunctional tumor is not excluded |
| Mild elevation without characteristic symptoms | Nonspecific; confirm fasting, medicine use, organ function, and specimen quality |
| Repeated clear elevation with diabetes, gallstones, steatorrhea, and weight loss | Supports somatostatinoma and warrants localization |
| High result in a patient taking a somatostatin analog | May be uninterpretable without assay-specific information and treatment timing |
| Normal result despite a pancreatic or duodenal mass | Does not rule out a nonfunctional neuroendocrine tumor or another tumor type |
There is no universally accepted concentration that by itself establishes somatostatinoma. Older descriptions sometimes refer to levels several times the upper limit, but assay methods and tumor secretion vary. The diagnosis is strongest when a reproducible elevation aligns with the syndrome and imaging.
A value just above the reference limit should not lead directly to surgery. The pretest probability is low, and analytical or physiological variation can exceed the difference. Repeating a fasting, properly handled sample may be appropriate.
The absolute value does not reliably indicate whether a tumor is malignant. Malignancy is assessed through local invasion, lymph-node or distant metastasis, histologic differentiation, mitotic activity, Ki-67 index, and growth over time. A small functional tumor can produce a large hormone effect, while a large tumor may release little measurable somatostatin.
A normal level does not exclude somatostatin receptor expression. Many neuroendocrine tumors express somatostatin receptors and respond to imaging or treatment with analogs without secreting excess somatostatin into blood.
Causes of High Somatostatin
Somatostatinoma is the principal disease associated with a marked, clinically relevant elevation, but other explanations must be considered.
Somatostatin-secreting neuroendocrine tumor
A functional tumor may arise from pancreatic delta cells or somatostatin-producing cells in the duodenum and periampullary region. Pancreatic lesions are often larger at diagnosis because symptoms are nonspecific and can be mistaken for ordinary diabetes or gallbladder disease. Duodenal lesions may be associated with neurofibromatosis type 1 and can contain psammoma bodies on pathology.
Other neuroendocrine tumors
Some medullary thyroid carcinomas, pheochromocytomas, or other neuroendocrine neoplasms can produce immunoreactive somatostatin. The level must be interpreted with the tumor phenotype and more specific biochemical tests. Somatostatin is not a screening test for these cancers.
Medicines
Synthetic somatostatin analogs are an obvious confounder. Whether the assay detects a particular analog depends on antibody specificity. Even without direct cross-reactivity, the drug changes secretion of insulin, glucagon, growth hormone, gastrointestinal hormones, and tumor products. Timing relative to a long-acting injection matters.
Kidney or liver dysfunction
Peptide clearance and metabolism can change with organ failure. Evidence for the magnitude is less standardized than for C-peptide or gastrin, but kidney and liver tests should be reviewed when a result is unexpected.
Acute illness and gastrointestinal conditions
Inflammation, stress, altered gut anatomy, or other gastrointestinal disease may influence local peptide release. Mild elevations in these settings are not specific for a tumor.
Analytical interference
Heterophile antibodies can bridge immunoassay antibodies and create a false high value. Cross-reactivity with somatostatin fragments or related peptides may vary. A result that does not fit the person’s glucose, digestive symptoms, imaging, or treatment should be repeated or investigated with another method.
The broader lesson is that the word “high” indicates a concentration above an assay’s reference boundary, not a complete diagnosis. Pretest probability, collection conditions, and biological coherence determine whether it is meaningful.
Somatostatinoma Symptoms and Diagnosis
Somatostatinoma syndrome reflects inhibition of several normal systems. The classic triad is diabetes, gallstones, and steatorrhea, often accompanied by weight loss. In practice, the full triad is uncommon and symptoms depend on tumor location and hormone output.
Hyperglycemia and diabetes
Somatostatin suppresses insulin. Glucose can rise, producing new diabetes or making existing diabetes harder to control. Glucagon is also suppressed, so the net effect depends on the balance of hormones and nutrition. Severe ketoacidosis is not the typical presentation, but any marked hyperglycemia requires standard evaluation.
Gallbladder disease
Inhibition of cholecystokinin reduces gallbladder contraction, promoting bile stasis and gallstones. A person may have right upper abdominal pain, nausea after fatty meals, inflammation, or duct obstruction. Gallstones are common in the general population, so they are persuasive only when combined with other features.
Diarrhea, steatorrhea, and weight loss
Suppression of pancreatic enzymes, bicarbonate, bile delivery, and intestinal absorption can produce bulky greasy stools, diarrhea, bloating, vitamin deficiency, and weight loss. The pattern overlaps with chronic pancreatitis, celiac disease, bile-acid disorders, small intestinal bacterial overgrowth, and other causes of malabsorption.
Other findings
Anemia, low protein, nutrient deficiency, abdominal pain, jaundice, gastrointestinal bleeding, or an abdominal mass may occur. Duodenal tumors can obstruct the bile or pancreatic duct. Some tumors are found incidentally without a hormone syndrome.
Diagnosis proceeds in stages:
- Identify a compatible clinical pattern.
- Confirm plasma somatostatin elevation with correct collection.
- Evaluate glucose, A1C, blood count, liver tests, nutrition, stool fat or fecal elastase when indicated, and gallbladder disease.
- Localize with contrast-enhanced CT or MRI.
- Use endoscopic ultrasound or somatostatin-receptor imaging when appropriate.
- Obtain tissue diagnosis and tumor grade when safe and necessary.
- Consider hereditary syndromes based on location, age, multiplicity, and family history.
Somatostatin-receptor PET imaging detects receptor expression rather than secreted somatostatin. A tumor can have a positive scan with a normal blood level. Conversely, not every lesion expresses receptors strongly enough for detection.
Pancreatic somatostatinomas can occur with multiple endocrine neoplasia type 1, while duodenal somatostatinomas have a recognized association with neurofibromatosis type 1. Genetic counseling is considered when clinical features support an inherited syndrome.
Low Levels and Related Tests
A low somatostatin concentration is rarely a stand-alone clinical diagnosis. Many healthy values are near the assay’s lower detection limit because the hormone acts locally and circulates briefly. Laboratories often provide only an upper reference limit.
Low measured levels may result from ordinary physiology, specimen degradation, or limited assay sensitivity. They do not prove delta-cell failure. There is no routine replacement therapy for isolated low somatostatin.
Somatostatin deficiency has been discussed in relation to diabetes and altered islet signaling, but a peripheral fasting blood test does not reliably measure local pancreatic paracrine activity. In type 1 diabetes, delta-cell regulation can be abnormal even when a serum concentration is not informative.
The correct related tests depend on the symptom:
- Diabetes or hyperglycemia: fasting glucose, A1C, ketones, C-peptide, and standard diabetes evaluation
- Gallstones: liver chemistry and ultrasound or other biliary imaging
- Steatorrhea: fecal elastase, stool fat, celiac testing, nutritional markers, and pancreatic imaging
- Secretory diarrhea: electrolytes, stool studies, laxative review, VIP, gastrin, calcitonin, or 5-HIAA when clinically indicated
- Pancreatic neuroendocrine tumor: syndrome-specific hormones, chromogranin A in selected cases, imaging, and pathology
- Acromegaly: IGF-1 and growth hormone suppression testing, not somatostatin concentration
A pancreatic hormone test panel evaluates other islet pathways but still does not provide a single endocrine-pancreas score. Each analyte should be ordered for a defined reason.
The pharmacologic effect of a somatostatin analog is assessed through the disease it treats. In acromegaly, clinicians follow IGF-1 and sometimes growth hormone. In neuroendocrine tumors, they follow symptoms, syndrome-specific markers, imaging, and tumor growth. Measuring endogenous somatostatin is not a routine drug-level test.
Limitations, Follow-Up, and Treatment
The test’s main limitations are the rarity of the target disease, fragile specimen requirements, limited assay standardization, and lack of a universally diagnostic cutoff. Mild abnormalities have low positive predictive value when the classic syndrome is absent.
Common pitfalls include:
- Ordering in a person with common diabetes and no tumor clues
- Failing to fast or process the sample immediately
- Ignoring octreotide, lanreotide, or pasireotide use
- Assuming normal blood somatostatin excludes a nonfunctional tumor
- Treating receptor-positive imaging as proof of hormone secretion
- Using the concentration to determine malignancy
- Comparing serial results from different laboratories
- Starting imaging or surgery for one borderline result
A repeated high result with compatible symptoms warrants endocrinology and neuroendocrine tumor expertise. The laboratory should confirm specimen integrity and possible interference. Imaging and tissue characterization then determine location, stage, and grade.
Treatment depends on resectability, symptoms, metastatic spread, receptor expression, and tumor biology. Surgery offers the best chance of cure for a localized resectable tumor. Somatostatin analogs may reduce secretion and slow growth in receptor-positive disease, despite the apparent paradox of treating somatostatin excess with an analog. Continuous receptor activation can suppress release of multiple tumor hormones and has antiproliferative effects.
Other options for advanced disease can include targeted therapy, peptide receptor radionuclide therapy, liver-directed treatment, chemotherapy, or additional surgery. Nutritional support, pancreatic enzymes, diabetes treatment, antidiarrheal therapy, gallbladder management, and replacement of fat-soluble vitamins may be required.
Monitoring uses symptoms, glucose, nutrition, imaging, and the hormone level only if it was reliably elevated at baseline. A change in somatostatin should be confirmed before treatment decisions because collection variability can be large.
Urgent evaluation is needed for severe dehydration, persistent vomiting, gastrointestinal bleeding, jaundice with fever, marked hyperglycemia, confusion, or symptoms of bowel or biliary obstruction. A send-out hormone result should never delay stabilization.
Somatostatin testing is most useful as a targeted biochemical clue. A correctly collected high level that matches diabetes, gallbladder disease, malabsorption, weight loss, and a neuroendocrine lesion can strengthen the diagnosis. Outside that setting, the result is too specialized and vulnerable to confounding to function as a general measure of pancreatic health.
Using Serial Results Carefully
Serial somatostatin measurements are most informative when the original concentration was clearly elevated, the same laboratory method is used, and collection conditions are reproduced. A change may reflect fasting duration, medication timing, specimen handling, kidney function, or assay variation rather than tumor growth. Imaging and clinical status should carry more weight than a small numerical shift.
Receptor imaging answers a different question from the blood test. Uptake indicates expression of somatostatin receptors and may support localization or treatment planning, but it does not prove that a lesion secretes somatostatin. Likewise, a nonavid lesion can still require tissue diagnosis when anatomic imaging and symptoms are concerning.
References
- Somatostatin Quantitative, Plasma 2026 (Laboratory test information)
- Somatostatin 2026 (Laboratory test information)
- Neuroendocrine Tumors | Choose the Right Test 2026 (Laboratory guidance)
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms 2025 (Review)
- The Landmark Series: Surgical Management of Functioning Pancreatic Neuroendocrine Tumors 2025 (Review)
Disclaimer
This article provides general education and does not diagnose somatostatinoma or another neuroendocrine tumor. Somatostatin results require specialist interpretation with fasting status, specimen handling, medicines, symptoms, imaging, and pathology. Severe dehydration, obstruction, bleeding, jaundice with fever, or marked glucose abnormalities require urgent medical care.
